Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Qi, Yanfeng ^a   Fu, Xueqi ^b   Xiong, Zhenggang ^a   Zhang, Haitao ^a,b   Hill, Steven M ^a   Rowan, Brian G ^a   Dong, Yan ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; KI 67 ANTIGEN; METHYLSELENINIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SELENIUM DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; METHYLSELENIC ACID; ORGANOSELENIUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; DRUG EFFECT; DRUG SCREENING;

MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICE; ORGANOSELENIUM COMPOUNDS; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863150004     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031539     Document Type: Article

References (38)

1. Kreike B, van KM, Horlings H, Weigelt B, Peterse H, et al. (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9: R65.
2. Cleator S, Heller W, Coombes RC, (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244.
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V, (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728.
4. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, et al. (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110: 876-884.
5. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, et al. (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20: 1913-1927.
6. Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, et al. (2004) A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 96: 696-703.
7. Li GX, Lee HJ, Wang Z, Hu H, Liao JD, et al. (2008) Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 29: 1005-1012.
8. Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, et al. (2004) A report of high-dose selenium supplementation: response and toxicities. Journal of Trace Elements in Medicine and Biology 18: 69-74.
9. Ip C, Thompson HJ, Zhu Z, Ganther HE, (2000) In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60: 2882-2886.
10. Ip C, (1998) Lessons from basic research in selenium and cancer prevention. J Nutr 128: 1845-1854.
11. Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, et al. (2009) Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila Pa) 2: 484-495.
12. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39-51.
13. Ohta Y, Kobayashi Y, Konishi S, Hirano S, (2009) Speciation analysis of selenium metabolites in urine and breath by HPLC- and GC-inductively coupled plasma-MS after administration of selenomethionine and methylselenocysteine to rats. Chem Res Toxicol 22: 1795-1801.
14. Hu H, Li GX, Wang L, Watts J, Combs GF Jr, et al. (2008) Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res 14: 1150-1158.
15. Hu H, Jiang C, Ip C, Rustum YM, Lu J, (2005) Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 11: 2379-2388.
16. Li S, Zhou Y, Dong Y, Ip C, (2007) Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Res 27: 3075-3082.
17. Li S, Zhou Y, Wang R, Zhang H, Dong Y, et al. (2007) Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 6: 1031-1038.
18. Vichai V, Kirtikara K, (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112-1116.
19. Liu S, Zhang H, Zhu L, Zhao L, Dong Y, (2008) Kruppel-like factor 4 is a novel mediator of selenium in growth inhibition. Mol Cancer Res 6: 306-313.
20. Liu S, Qi Y, Ge Y, Duplessis T, Rowan BG, et al. (2010) Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. Mol Cancer Ther 9: 2016-2025.
21. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C, (2003) Delineation of the Molecular Basis for Selenium-induced Growth Arrest in Human Prostate Cancer Cells by Oligonucleotide Array. Cancer Res 63: 52-59.
22. Jiang W, Jiang C, Pei H, Wang L, Zhang J, et al. (2009) In vivo molecular mediators of cancer growth suppression and apoptosis by selenium in mammary and prostate models: lack of involvement of gadd genes. Mol Cancer Ther 8: 682-691.
23. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J, (2010) ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12: R56.
24. Adams LS, Kanaya N, Phung S, Liu Z, Chen S, (2011) Whole Blueberry Powder Modulates the Growth and Metastasis of MDA-MB-231 Triple Negative Breast Tumors in Nude Mice. J Nutr.
25. Fost C, Duwe F, Hellriegel M, Schweyer S, Emons G, et al. (2011) Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 25: 1481-1487.
26. Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, et al. (2010) Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 5: e13831.
27. Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, et al. (2011) YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol 39: 569-575.
28. Zeng Q, Yang Z, Gao YJ, Yuan H, Cui K, et al. (2010) Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. Eur J Cancer 46: 1132-1143.
29. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
30. Chou TC, Talaly P, (1977) A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252: 6438-6442.
31. Bhalla KN, (2003) Microtubule-targeted anticancer agents and apoptosis. Oncogene 22: 9075-9086.
32. Matsuyoshi S, Shimada K, Nakamura M, Ishida E, Konishi N, (2006) Bcl-2 phosphorylation has pathological significance in human breast cancer. Pathobiology 73: 205-212.
33. Matsuyoshi S, Shimada K, Nakamura M, Ishida E, Konishi N, (2006) FADD phosphorylation is critical for cell cycle regulation in breast cancer cells. Br J Cancer 94: 532-539.
34. Rieder CL, Maiato H, (2004) Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 7: 637-651.
35. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
36. Suzana S, Cham BG, Ahmad RG, Mohd RR, Fairulnizal MN, et al. (2009) Relationship between selenium and breast cancer: a case-control study in the Klang Valley. Singapore Med J 50: 265-269.
37. Kotsopoulos J, Chen Z, Vallis KA, Poll A, Ghadirian P, et al. (2010) Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers. Cancer Causes Control 21: 679-687.
38. Vogt TM, Ziegler RG, Patterson BH, Graubard BI, (2007) Racial differences in serum selenium concentration: analysis of US population data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 166: 280-288.